Rare disease
Genglycos · glycogen storage disease Ia
Accelerated approval · As of
The DTX401 phase 3 study measured daily cornstarch use. FDA required further evidence of clinical benefit after accelerated approval.
Milestone history
The phase 3 study DTX401-CL301 (NCT05139316) began.
ClinicalTrials.govThe study reached its recorded completion date.
ClinicalTrials.govFDA granted accelerated approval as an adjunct to nutritional management for patients aged eight and older.
FDAClinicalTrials.gov posted the study’s first results tables.
ClinicalTrials.gov